Literature DB >> 8409658

Surgical management of recurrent carpal tunnel syndrome.

B Chang1, A L Dellon.   

Abstract

An approach to the surgical management of recurrent carpal tunnel syndrome was evaluated in 30 patients with 35 involved wrists. This includes internal neurolysis of the median nerve and early post-operative mobilization of the wrist and fingers. The preferred surgical approach is through a second, more ulnar incision. Clinical assessment of sensorimotor function was converted into a numerical score ranging from zero (normal) to 9 (anaesthesia) and 10 (atrophy, severe). The average pre-operative score was mean 6.5 and median 7. At a mean follow-up of 23.5 months, the average post-operative score was mean 1.8 and median 0, a statistically significant improvement (P < 0.001).

Entities:  

Mesh:

Year:  1993        PMID: 8409658     DOI: 10.1016/0266-7681(93)90148-9

Source DB:  PubMed          Journal:  J Hand Surg Br        ISSN: 0266-7681


  4 in total

1.  Revision carpal tunnel surgery: a 10-year review of intraoperative findings and outcomes.

Authors:  Lawrence Zieske; Gregory C Ebersole; Kristen Davidge; Ida Fox; Susan E Mackinnon
Journal:  J Hand Surg Am       Date:  2013-06-25       Impact factor: 2.230

2.  Recurrent and persistent carpal tunnel syndrome: "Triple-therapy approach".

Authors:  Amanda F Spielman; Sriram Sankaranarayanan; Piotr Skowronski; Anne-Sophie Lessard; Zubin Panthaki
Journal:  J Orthop       Date:  2020-09-29

3.  The Effectiveness of Hydrodissection with 5% Dextrose for Persistent and Recurrent Carpal Tunnel Syndrome: A Retrospective Study.

Authors:  Ta-Chung Chao; Kenneth Dean Reeves; King Hei Stanley Lam; Tsung-Ying Li; Yung-Tsan Wu
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

Review 4.  Evidence-Based Approach to Timing of Nerve Surgery: A Review.

Authors:  Brendan J MacKay; Cameron T Cox; Ian L Valerio; Jeffrey A Greenberg; Gregory M Buncke; Peter J Evans; Deana M Mercer; Desirae M McKee; Ivica Ducic
Journal:  Ann Plast Surg       Date:  2021-09-01       Impact factor: 1.539

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.